Although CD13 may be a potential therapeutic target for alleviating drug resistance in HCC therapy, the potential role and underlying molecular regulation mechanism by which CD13 contributes to the sorafenib resistance remain poorly understood. Here, ANPEP is linked to hepatocellular carcinoma.